Skip to content
Michael A. Ladrigan, M.D.

Michael A. Ladrigan, M.D.

Emergency Medicine

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Not Accepting New Patients

Contact

Appointment (585) 275-5730

About Me

Professional Background

Dr. Michael Ladrigan is a Rochester native, who did his undergraduate education at Villanova University. In 2001 he began his medical school training at SUNY Buffalo, and graduated with honors in 2005. His Emergency Medicine residency was done here, at the University of Rochester; he graduated fro...
Dr. Michael Ladrigan is a Rochester native, who did his undergraduate education at Villanova University. In 2001 he began his medical school training at SUNY Buffalo, and graduated with honors in 2005. His Emergency Medicine residency was done here, at the University of Rochester; he graduated from the program in 2008. He is board certified in Emergency Medicine, and practices both at the University of Rochester Medical Center and at community sites within the regional University of Rochester Medicine system.

Certified Specialties

Emergency Medicine - American Board of Emergency Medicine

Faculty Appointments

Assistant Professor of Clinical Emergency Medicine - Department of Emergency Medicine (SMD)

Credentials

Residency & Fellowship

Residency, Emergency Medicine, University of Rochester Medical Center. 2006 - 2008

Internship, Emergency Medicine, University of Rochester Medical Center. 2005 - 2006

Education

MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 2005

Awards

Strong Star. 2013 - 2016

Emergency Medicine Resident Teaching Award. 2008

Employee of the Month. 2000

Alpha Epsilon Delta Honor Society. 1995

Publications

Journal Articles

A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.

Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K

Cancer gene therapy.. 2003 April 10 (4):251-9. Epub 1900 01 01.